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Abstract Recent evidence suggests the Akt-mTOR
pathway may play a role in development of low-grade
gliomas (LGG). We sought to evaluate whether activation
of this pathway correlates with survival in LGG by
examining expression patterns of proteins within this
pathway. Forty-ﬁve LGG tumor specimens from newly
diagnosed patients were analyzed for methylation of the
putative 50-promoter region of PTEN using methylation-
speciﬁc PCR as well as phosphorylation of S6 and PRAS40
and expression of PTEN protein using immunohistochem-
istry. Relationships between molecular markers and overall
survival (OS) were assessed using Kaplan-Meier methods
and exact log-rank test. Correlation between molecular
markers was determined using the Mann-Whitney U and
Spearman Rank Correlation tests. Eight of the 26 patients
with methylated PTEN died, as compared to 1 of 19
without methylation. There was a trend towards statistical
signiﬁcance, with PTEN methylated patients having
decreased survival (P = 0.128). Eight of 29 patients that
expressed phospho-S6 died, whereas all 9 patients lacking
p-S6 expression were alive at last follow-up. There was an
inverse relationship between expression of phospho-S6 and
survival (P = 0.029). There was a trend towards decreased
survival in patients expressing phospho-PRAS40
(P = 0.077). Analyses of relationships between molecular
markers demonstrated a statistically signiﬁcant positive
correlation between expression of p-S6(235) and
p-PRAS40 (P = 0.04); expression of p-S6(240) correlated
positively with PTEN methylation (P = 0.04) and nega-
tively with PTEN expression (P = 0.03). Survival of LGG
patients correlates with phosphorylation of S6 protein. This
relationship supports the use of selective mTOR inhibitors
in the treatment of low grade glioma.
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Introduction
Low-grade gliomas (LGGs) are relatively slow growing
neoplasms of the central nervous system (CNS) that com-
prise approximately 20% of all glial tumors. They can be
divided into two broad categories based on their histological
characteristics—Grade I and Grade II lesions. This paper
will primarily focus on Grade II lesions, with astrocytomas
being the predominant histological sub-type, constituting
35% of low-grade lesions and generally having a worse
prognosis than the oligodendroglial or mixed variants.
The mainstay treatment for adult Grade II lesions,
regardless of histology, has remained largely unchanged
for decades, with surgical resection at presentation and
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namely temozolomide, has proven of some beneﬁt in
recurrent disease [1]. However, further therapeutic gain
requires increased knowledge of the basic biology driving
the tumor phenotype in these lesions.
Over the past few years, several key discoveries related
to LGG biology have been made. Notably, in approxi-
mately 60% of astrocytomas, there is inactivation of the
TP53 locus, while in over 80% of oligodendroglial lesions
there is allelic loss of chromosome 1p and 19q [2, 3]. Both
variants can also exhibit overexpression of the platelet
derived growth factor (PDGF) and its receptor [4, 5].
1p/19q status in oligodendrogliomas also appears to cor-
relate with promoter methylation of the DNA repair
enzyme O6-Methylguanine-DNA methyltransferase
(MGMT); in patients with 1p/19q deletions, upwards of
85% have concomitant MGMT methylation. This is
important from a prognostic standpoint as MGMT hyper-
methylated tumors tend to be more chemosensitive [6].
More recently, we found PTEN hypermethylation in
upwards of 50% of Grade II astrocytomas, oligodendro-
gliomas,andmixedhistologies.PTENisanegativeregulator
of the phosphoinositide 3-kinase (PI3K) signal transduction
pathway. Sitting downstream of PI3K is the mammalian
target of rapamycin (mTOR), a 289-kDa serine/threonine
kinase that phosphorylates a series of downstream effectors
involved in protein biosynthesis, ribosome biogenesis, and
the transcription of genes crucial to cell growth [7, 8].
Because of this pleiotropy, the mTOR pathway is frequently
up-regulated ina varietyofneoplasms andhas been targeted
for therapeutic intervention [9–11]. In fact, rapamycin has
already been shown to have some antitumor activity in
PTEN-deﬁcient glioblastoma [12, 13]. Rapamycin, and its
derivatives temsirolimus and everolimus inhibit the kinase
activity of mTOR by binding to FK506 binding protein 12
(FKBP12), which then binds to the mTORC1 complex.
Of interest, PTEN hypermethylation was found in
approximately 80% of the examined secondary glioblas-
tomas, lesions that themselves result from the malignant
transformation of lower-grade lesions. This enrichment for
hypermethylation in the high grade recurrences suggested
that this epigenetic modiﬁcation and the resultant up-reg-
ulation of the PI3K-mTOR pathway might play a crucial
role in the biology of LGGs and thus have a signiﬁcant
prognostic impact.
Towards that end, we decided to examine Grade II adult
lesions in order to determine the relationship between
overall survival (OS) and the methylation status and
expression of PTEN and the phosphorylation of proteins in
the PI3K-mTOR pathway, speciﬁcally S6 and PRAS40
[14, 15]. We hypothesized that those patients with PTEN
promoter hypermethylation, phosphorylation of S6, or
phosphorylation of PRAS40 (because any of these changes
might result in increased ﬂux through the PI3K-mTOR
pathway) would have decreased overall survival. Results
we present here show that, in univariate analyses, there is a
statistically signiﬁcant inverse relationship between OS
and phosphorylation of S6. Additionally, PTEN promoter
methylation, PTEN protein expression, and phosphoryla-
tion of PRAS40 show a weaker statistical correlation with
OS. The up-regulation of PI3K-mTOR pathway compo-
nents and their apparent relationship to survival suggest
that agents that selectively inhibit this pathway may have a
role in the treatment of Grade II gliomas.
Materials and methods
Patients and tissue samples
Frozen tissue and formalin-ﬁxed, parafﬁn-embedded sec-
tions from forty-ﬁve LGG (grade II) tumor specimens from
newly diagnosed patients were obtainedfrom the University
of California, San Francisco Brain Tumor Research Center
tissue bank, under appropriate institutional review board
approval. Female to male ratio was 21:24. Twenty-two
patients had astrocytomas (49%), 16 oligodendrogliomas
(35%), and seven mixed histology (16%). Median age at
diagnosis was 37 years (range: 20–64). All ages are given at
the time of surgery, which occurred at the University of
California, San Francisco between 1990 and 2003.
DNA preparation and bisulﬁte treatment
Genomic DNA was isolated from approximately 25 mg
wet weight of frozen tissue sample using QIAamp DNA
Mini Kit (Qiagen Inc., Valencia, CA, USA) according to
the manufacturer’s instructions and eluted twice in a total
of 100 ll of elution buffer. This procedure yielded 5–40 lg
of DNA. Bisulﬁte modiﬁcation of genomic DNA was
performed as described previously. Brieﬂy, 1 lg puriﬁed
DNA was diluted in 36 llH 2O, 4 ll 3.0 M NaOH was
added, and DNA was denatured at 37C for 15 min. The
samples were then treated with 416 ll 3.6 M sodium
bisulﬁte solution (pH 5.0) and 24 ll of 10 mM hydroqui-
none. All solutions were prepared fresh for each analysis.
Samples were incubated at 55C for 16 h. Two drops of
mineral oil were layered on top of the solution to prevent
evaporation. Bisulﬁte-modiﬁed DNA was puriﬁed with the
Wizard DNA Clean-up System and vacuum manifold
(Promega, Madison, WI, USA) according to the manufac-
turer’s manual. Freshly prepared NaOH solution was added
to a ﬁnal concentration of 0.3 M, and samples were incu-
bated at 37C for 15 min, followed by neutralization with
ammonium acetate (pH 7.0; ﬁnal concentration, 3.0 M) and
ethanol precipitation. Normal human peripheral blood
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DNA methylase (M. Sss I; New England BioLabs, Beverly,
MA, USA), were also modiﬁed as positive and negative
controls, respectively.
Methylation-speciﬁc PCR
To examine whether the PTEN promoter is methylated in
glioma specimens, we used methylation-speciﬁc primers
that had previously been used to demonstrate methylation
of the PTEN promoter in a subset of non-small-cell lung
cancer samples. These primers amplify a 181-base pair
region of the PTEN promoter that starts 2,477 nucleotides
upstream from the translation start site—methylated
primers: forward, 50-GTTTGGGGATTTTTTTTTCGC-30;
reverse, 50-AACCCTTCCTACGCCGCG-30; unmethylated
primers: forward, 50-TATTAGTTTGGGGATTTTTTTTT
TGT-30; reverse, 50-CCCAACCCTTCCTACACCACA-30.
It should be noted that these primers do not amplify the
highly homologous PTEN pseudogene located on chro-
mosome 9p21, as these sequences lie outside the region of
similarity.
The 25 ll PCR reaction contained 25 ng bisulﬁte DNA,
2% dimethylsulfoxide, 1.5 mM MgCl2, and 1 U Ampli Taq
Gold DNA polymerase (Applied Biosystems, Foster City,
CA, USA). PCR reactions were cycled in a Gene Amp
2700 thermocycler (Applied Biosystems) under the fol-
lowing conditions: preheat at 95C for 10 min, 95C for
30 s, 62C for 30 s, 72C for 30 s, 38 cycles, and a ﬁnal
extension at 72C for 7 min. Aliquots (12 ll) of methyla-
tion-speciﬁc PCR (MSP) products were analyzed on 3%
agarose gels, stained with ethidium bromide, and visual-
ized under UV illumination. Results were recorded with a
digital imaging system. For each PCR experiment, DNA
from peripheral blood of normal blood donors treated with
and without CpG methylase and bisulﬁte was included as
positive and negative controls, respectively. We repeated
MSP assays on all samples and found no discordant results
among replicates. The MSP assay is sensitive to approxi-
mately 5% methylated product. To conﬁrm the efﬁciency
of the bisulﬁte modiﬁcation and the speciﬁcity of MSP,
bisulﬁte sequencing of the PCR products was carried out
using the procedure reported previously.
Immunohistochemistry
All tissue was routinely ﬁxed in either phosphate buffered
4% formalin or Zn-4% Formalin, dehydrated by graded
ethanols and embedded in wax (Paraplast Plus, McCormick
Scientiﬁc) using routine techniques. All sections were 5 l
on Superfrost/Plus slides (Fisher Scientiﬁc, Pittsburgh, PA,
USA). The following antibodies were obtained from com-
mercial sources and used at following dilutions and
incubation times/temperatures: 1) rabbit polyclonal phos-
pho-S6 ribosomal protein (Ser235/236; Cell Signaling
#2211) 1:200, 32 min/37; 2) rabbit polyclonal phospho-S6
ribosomal protein (Ser240/244; Cell Signaling #2215)
1:200, 32 min/37; 3) rabbit monoclonal PTEN (138G6;
Cell Signaling #9559) at 1:50-1:100, 32 min/37; 4) rabbit
polyclonal phospho-PRAS40 (Invitrogen#441100G) 1:100,
32 min/37; and 5) rabbit polyclonal MIB-1; [Ventana
Medical Systems Anti-Ki-67(30-9)], 2lg/ml/32 min/37.
Antigen retrieval for phospho-S6 (both epitopes) and
phospho-PRAS40 was performed for 30 min in Tris buffer
pH8at90;forPTEN andMIB-1retrievaltimewas16 min.
Following antigen-retrieval, sections were treated with 3%
methanol-hydrogen peroxide at 22C for 16 min for PTEN
and MIB-1 and for 32 min for the phospho-PRAS40 and
phospho-S6 epitopes. All immunohistochemistry assays
were performed on the Ventana Medical Systems Bench-
mark XT using the Ultraview (multimer) detection system.
All slides were then scored. One score was assigned to
each slide based upon the percentage of visible cells that
stained positive. For the percentage staining positive, a
score of 0 denoted no positive cells; a score of 1 meant that
1–33% of cells stained positive; 2 for 33–66% of cells; and
3 for [66% of cells. Immunohistochemistry scoring was
performed in an entirely blinded fashion.
Statistics
All statistical analyses were performed using Statistica 6.0
(StatSoft, Tulsa, OK) and StatXact-8 (Cytel, Cambridge,
MA). Overall survival was deﬁned as the period between
resection and death or date last known alive. Kaplan-Meier
methods were used to estimate overall survival. All P
values in the survival analysis were determined by the
exact log–rank test and are two-tailed. Because of the small
sample size and few events, only univariate analysis was
possible. Correlative analysis between the biological vari-
ables investigated was done using the same software.
P values were derived using the Mann-Whitney U test or
Spearman’s rank test for correlation. Due to the exploratory
nature of these analyses, no adjustment for multiple com-
parisons was made; statistical signiﬁcance was deﬁned as a
P value\0.05 in all cases.
In analyzing IHC scores in relationship with survival,
we considered the following approaches to divide the
samples into two groups: (1) no (0) vs. positive (C1)
staining; or (2) scores of 0/1 vs. scores of 2/3 staining. We
found that while the latter approach did not yield statisti-
cally signiﬁcant relationships to OS (P = 0.104 for PTEN;
P = 0.38 for p-S6 235/236; P = 0.39 for p-S6 240;
P = 0.37 for p-PRAS40), we were able to establish a more
robust relationship to OS with the former method of
grouping. This discrepancy may be explained by the impact
J Neurooncol (2010) 97:33–40 35
123of small sample size on the sampling distributions. Nev-
ertheless, there was generally a consistent survival trend
using either approach.
Results
Table 1 summarizes patient baseline characteristics and
length of follow-up among surviving patients, according to
status of each molecular marker. At the time of analysis,
nine patients had died. Median follow up for those still
alive was 5.8 years (range: 0.01–11.7). Survival data was
acquired for all 45 patients; however in a small number of
patients there was not sufﬁcient material to complete each
and every molecular analysis.
Table 2 presents the distribution of the IHC based assay
results. Only a small fraction of samples scored three for all
biological variables while the majority of the samples were
scored 0 or 1. Figure 1 illustrates positive staining for each
of the four immunohistochemical assays performed; each of
the four panels in the ﬁgure displays a separate tumor that
receivedascoreof3forPTEN,phospho-PRAS40,phospho-
S6 (Ser235/236), or phospho-S6 (240/244), respectively.
Figure 2 presents the Kaplan-Meier plots of survival
with respect to each biological variable. For PTEN meth-
ylation, there was no statistically signiﬁcant relationship
between methylation status and overall-survival (OS)
(P = 0.128). At the time of the analysis, 4 of the 10
patients with PTEN expression by IHC died, as compared
to 3 of 23 patients who did not express PTEN. There was a
trend towards a statistically signiﬁcant difference in sur-
vival (P = 0.098) that favored those patients whose tumors
did not express PTEN (Fig. 2). The estimated 5-year sur-
vival for patients with PTEN expression was 68%, as
compared to 90% for those patients not expressing PTEN.
Median follow-up for surviving patients who did not
express PTEN was 5.76 years (0.01–11.69 years); for those
surviving patients who were PTEN positive, median fol-
low-up was 6.06 years (3.54–9.98 years).
We assessed the phosphorylation status of two S6 epi-
topes: Ser-235/236 and Ser-240. Data on phosphorylation
of Ser-235/36 was available on 38 patients (84%) and of
those, 29 (76%) were phosphorylated. There was a statis-
tically signiﬁcant inverse relationship between OS and
phosphorylation of the 235/236 epitope (P = 0.045)
(Fig. 2); eight patients with phosphorylation at the 235/236
site died, whereas all patients without phosphorylation
were alive at last follow-up. Median follow-up for sur-
viving patients with phosphorylation was 5.3 years (0.10–
10.98) versus 8.59 years (0.57–11.69) for those without.
The estimated 5-year survival for patients with phosphor-
ylation of S6 Ser-235/236 was 76%, as compared to 100%
for patients without.
With respect to phosphorylation of the S6 Ser-240 epi-
tope, again 84% of samples were included in the analysis,
with 76% phosphorylated. There was an even more robust,
statistically signiﬁcant inverse relationship between phos-
phorylation of Ser-240 and OS (P = 0.029) (Fig. 2).
Similar to the 235/236 epitope, there were eight deaths in
the phosphorylated group and none in the negative group.
Median follow-up for surviving patients with phosphory-
lation was 5.58 years (0.01–11.69) versus 7.19 years
(0.57–11.5 years) for the negative group. The estimated 5-
year survivals were the same as they were for the Ser-235/
36 groupings. Since tumor histology may play an important
role in evaluating the relationship between molecular
variables and survival, we further examined the association
between survival and phosphorylation of Ser-240 (the
marker that was found to be most predictive of survival in
our study) separately for astrocytomas (n = 22) and oli-
godendrogliomas (n = 16). Among these patients, 6/22
astrocytomas and 2/16 oligodendragliomas had died. All
eight deaths demonstrated Ser-240 phosphorylation.
Within each histologic subtype, we again found a consis-
tent pattern of decreased survival among patients with Ser-
240 phosphorylation even though the log-rank test did not
reach statistical signiﬁcance for either subgroup due to
small event number (P = 0.137 and P = 0.301 for astro-
cytoma and oligodendraglioma, respectively).
We also assessed the relationship between phosphory-
lation of PRAS40 and OS in 35 patients. Eighteen of these
patients (51%) had positive p-PRAS40 expression. There
were six deaths in the positive group, and one in the neg-
ative group. There was a trend towards decreased survival
for those patients whose tumors expressed any p-PRAS40
(P-value = 0.077). The 5-year survival for patients who
expressed p-PRAS40 was 75 versus 94% for patients
without expression. Median follow-up for survivors with
and without p-PRAS40 was 5.8 years (0.01–10.98) and
5.8 years (0.57–11.69), respectively.
There was a positive correlation between p-S6 (235/36)
staining and p-PRAS40 staining (P-value = 0.04); there
was also a near perfect positive correlation between the
staining for the two S6 epitopes (P B 0.001). The expres-
sion of p-S6 (240) was correlated positively with PTEN
methylation (P = 0.04) and negatively with PTEN-
expression (P = 0.03).
In examining the baseline variables, there did not appear
to be any severe imbalance in the distributions with respect
to the biological variables (Table 1). However, in the
variable found to be most predictive of survival based on
univariate analysis (i.e. p-S6 Ser-240), a relatively higher
percentage of phospho-negative patients had gross total
resections. To conﬁrm that the signiﬁcant survival advan-
tage we observed among patients without p-S6-240 phos-
phorylation was not a result of a larger fraction with gross
36 J Neurooncol (2010) 97:33–40
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123total resection, we further assessed if p-S6-240 was pre-
dictive of survival in the subset of patients who only had
subtotal resections. Among this subset of 23 patients, the
trend towards decreased survival among those with p-S6-
240 phosphorylation persisted (Fig. 2), even though the
statistical test was no longer signiﬁcant (P = 0.068). This
may be due to the decease in sample size. It is also note-
worthy that the eight patients with p-S6-240 phosphoryla-
tion who died all had had subtotal resections.
Discussion
We know that the mTOR pathway plays a crucial role in
the tumorigenesis of a variety of solid malignancies. The
pathway, when activated, ampliﬁes protein transcription,
intensiﬁes cell growth, and halts apoptosis. More recent
evidence implicates PTEN promoter methylation, and by
extension mTOR activation, in the malignant progression
of LGGs. We reasoned that if this association were
clinically signiﬁcant, mTOR activation in LGG patients
would portend a worse prognosis. We therefore sought to
demonstrate a relationship between activation of this
pathway and survival in LGG by examining several key
proteins in the pathway. Such an association would provide
justiﬁcation for the use mTOR inhibitors in the treatment of
LGG.
PTEN is a tumor suppressor that inhibits ﬂux through
the mTOR pathway. We would expect patients with PTEN
promoter hypermethylation to have increased mTOR
activity and thus decreased OS. The relationship between
promoter hypermethylation and OS demonstrated a statis-
tical trend that did not reach signiﬁcance. It is possible that
a larger study will provide greater statistical power to
demonstrate a true correlation between PTEN promoter
hypermethylation and OS if one exists; however, such an
endeavor would require a much greater multi-institutional
effort that we hope to accomplish in the future. With
regards to PTEN protein expression and contrary to what
we know about PTEN’s tumor suppressive activities, we
found those patients with expression had a trend towards
decreased OS, although this association was not statisti-
cally signiﬁcant. However, because of the challenges
involved with the PTEN IHC assay, one must use caution
in interpreting this particular result.
PRAS40 is a protein that, when phosphorylated, no
longer acts to inhibit the mTOR pathway; S6 is a down-
stream target of the mTOR effector p70S6K that is
Table 2 Distribution of IHC assay results
0123
PTEN-expression 23 (70%) 5 (15%) 3 (9%) 2 (6%)
P-S6 Ser 235 9 (24%) 17 (45%) 10 (26%) 2 (5%)
P-S6 Ser 240 9 (24%) 21 (55%) 7 (18%) 1 (3%)
P-PRAS40 17 (49%) 11 (31%) 4 (11%) 3 (9%)
Fig. 1 Examples of scores of 3
for each of the four
immunohistochemical assays
performed; each of the four
panels in the ﬁgure displays a
separate tumor that received a
score of 3 for PTEN, phospho-
PRAS40, phospho-S6 (Ser235/
236), or phospho-S6 (240/244),
respectively
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123activated by phosphorylation. In univariate analyses, we
established a correlation between phosphorylation of these
two proteins and OS in LGG; patients whose tumors had
evidence of either PRAS40 or S6 phosphorylation had
decreased OS. This effect is presumably mediated by the
pro-tumorigenic consequences of mTOR signaling, of
which these two proteins are participants. One would
additionally assume that if the common mTOR pathway
linking these proteins was activated, their phosphorylation
would correlate. Indeed, we found signiﬁcant positive
correlations between S6 phosphorylation and both PRAS40
phosphorylation and PTEN methylation as well as a sig-
niﬁcant negative correlation between S6 phosphorylation
and PTEN expression. Finally, the near-perfect correlation
between phosphorylation at the two S6 epitopes provides
good internal validation of our IHC protocol.
Because small patient numbers precluded multivariate
analysis, possible confounding exists. The most likely
confounders are differences in age, treatments used, and
surgical outcomes between groups of patients whose
tumors varied in their molecular markers. We found no
statistically signiﬁcant relationship between treatment with
chemotherapy or radiation and OS. Therefore, it is unlikely
that differences in the number of patients who had received
either chemotherapy or radiation between groups with and
without phosphorylation of S6 and PRAS40 and with and
without expression of PTEN confounded our conclusions.
Furthermore, there appeared to be no dramatic differences
between median age and histological mix when comparing
groups with different molecular markers.
However, again looking at the patient population as a
whole, we did ﬁnd a statistically signiﬁcant relationship
between extent of resection (EOR) and OS; those patients
who had undergone gross-total resections of their tumors
had longer survival. As mentioned, for the variable most
predictive of survival (p-S6-Ser 240), we did ﬁnd that the
negative expression group did have a higher percentage of
patients with gross-total resection. However, even by
looking exclusively at the group of patients with subtotal
resections, phospho-S6 expression still portended a worse
overall survival, exhibiting a statistical trend nearing sig-
niﬁcance (P = 0.068).
Of note, inhibitors of mTOR have proven largely inef-
fectual in glioblastoma [16]. This may be due to greater
genetic complexity and activation of redundant pathways
in glioblastoma compared to lower grade gliomas. In
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123addition, mTOR drives a feedback loop that normally
keeps PI3K activity in check and mTOR inhibition can
alleviate this negative feedback loop and result in activa-
tion of PI3K. Therefore, abrogation of this negative loop
may impede anti-tumor efﬁcacy of mTOR inhibitors [13].
Ultimately, larger cohorts that will likely require multi-
institutional efforts, are needed to validate our ﬁndings.
Our data support a novel role for activation of PI3K/
mTOR signaling in LGGs, and provide a compelling
rationale for the use of mTOR inhibitors in the treatment
of LGG. Such studies are ongoing in adults and children
and will greatly beneﬁt from incorporation of molecular
analyses that may predict clinical outcome and identify
those patients most likely to beneﬁt from targeted
therapies.
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